Tests tradipitant for nausea and vomiting caused by GLP-1R agonist medicines
Tests tradipitant against placebo in adults with overweight or obesity.
Key facts
- Who runs it
- Vanda Pharmaceuticals
- Where
- Burke, Hamilton, Los Angeles, New York, Plano, San Antonio, San Diego, San Jose, Syosset, and Tampa, United StatesSee the 10 sites
- Trial code
- Registry title
- A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 280 people, planned
- Started
- 27 Mar 2026
- Expected to end
- 1 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Tradipitant
- Placebo
- Record updated
- 20 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 65 who are overweight or have obesity and have no serious medical problems or chronic diseases. It tests tradipitant against placebo for nausea and vomiting after a GLP-1R agonist.
- Age
- 18 Years to 65 Years
- Sex
- All sexes can join.
- Disease stage
- Body Mass Index ≥ 25 and < 40 kg/m^2. No serious medical problems or chronic diseases.
- Earlier treatment
- People who took any investigational medication within the past 60 days cannot join.
Main reasons for not taking part
- Type I or type II diabetes
- Another disorder that contributes to gastrointestinal symptoms
- History of intolerance or hypersensitivity to NK-1 receptor antagonists
- History of intolerance or hypersensitivity to GLP-1 receptor agonists
- Any investigational medication within the past 60 days
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Body Mass Index ≥ 25 and < 40 kg/m\^2
- No serious medical problems or chronic diseases, specifically no type I or type II diabetes
Who cannot take part
- Exposure to any investigational medication within the past 60 days
- Another disorder that contributes to gastrointestinal symptoms
- History of intolerance and/or hypersensitivity to NK-1 receptor antagonists
- History of intolerance and/or hypersensitivity to GLP-1 receptor agonists
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
- Burke, VirginiaHospital not named in the registryContact: Vanda PharmaceuticalsNot yet recruiting
- Hamilton, New JerseyHospital not named in the registryContact: Vanda PharmaceuticalsNot yet recruiting
- Los Angeles, CaliforniaHospital not named in the registryContact: Vanda PharmaceuticalsTaking people
- New YorkHospital not named in the registryContact: Vanda PharmaceuticalsNot yet recruiting
- Plano, TexasHospital not named in the registryContact: Vanda PharmaceuticalsNot yet recruiting
- San Antonio, TexasHospital not named in the registryContact: Vanda PharmaceuticalsNot yet recruiting
- San Diego, CaliforniaHospital not named in the registryContact: Vanda PharmaceuticalsTaking people
- San Jose, CaliforniaHospital not named in the registryContact: Vanda PharmaceuticalsNot yet recruiting
- Syosset, New YorkHospital not named in the registryContact: Vanda PharmaceuticalsNot yet recruiting
- Tampa, FloridaHospital not named in the registryContact: Vanda PharmaceuticalsTaking people
About the trial
What the trial wants to find out
The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one weight-related condition. The study is placebo-controlled with two treatment arms.
The 2 groups in the trial
- Placebo GroupPlacebo, for comparison
Treatment with placebo BID for approximately 2 weeks
Treatment: Placebo
- Tradipitant GroupTreatment being tested
Treatment with tradipitant BID for approximately 2 weeks
Treatment: Tradipitant
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The Thetis Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Tradipitant on Nausea and Vomiting After GLP-1R Agonist Administration in Healthy Overweight or Obese Volunteers
- Plain-language title
- Tests tradipitant for nausea and vomiting caused by GLP-1R agonist medicinesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07446439, who can take part
- Record updated
- 20 April 2026